SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the full year ended December 31, 2014.
“Since the beginning of 2014, we have made significant progress toward our goal of becoming a leading precision oncology biotechnology company,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “We made substantial strides with our lead product candidate entrectinib on both the clinical and regulatory fronts, we achieved CLIA registration of our in-house diagnostics laboratory, we acquired rights to a number of additional promising development programs and we have bolstered our balance sheet and strengthened our team.
Help employers find you! Check out all the jobs and post your resume.
“Since the beginning of 2014, we have made significant progress toward our goal of becoming a leading precision oncology biotechnology company,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “We made substantial strides with our lead product candidate entrectinib on both the clinical and regulatory fronts, we achieved CLIA registration of our in-house diagnostics laboratory, we acquired rights to a number of additional promising development programs and we have bolstered our balance sheet and strengthened our team.
Help employers find you! Check out all the jobs and post your resume.
